Asterias biotherapeutics, inc. (AST)
Income statement / Quarterly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
us-gaap_GrantMember
License Revenue [Member]
Royalties from Product Sales [Member]
REVENUE
Total revenue

116

109

-

-

1,688

316

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant income

-

-

0

-

-

-

1,894

1,707

1,858

1,520

1,487

601

1,070

659

677

1,035

0

0

0

-

-

-

-

0

Sale of cell lines

-

-

-

-

-

-

-

-

-

-

-

-

0

40

-

-

0

0

-

-

-

-

-

-

License revenue

-

-

366

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalties from product sales

-

-

112

-

-

-

116

-80

218

12

107

7

353

73

102

21

85

21

61

-

-

-

-

0

Total revenues

-

-

478

-

-

-

2,010

1,752

2,076

1,532

1,594

608

1,423

772

779

1,056

85

21

61

0

0

0

0

0

Cost of sales

57

57

63

13

81

18

53

10

59

6

53

3

176

38

51

12

42

41

0

-

0

0

-

0

Gross profit

59

52

415

15

1,607

298

1,957

1,742

2,017

1,526

1,541

605

1,247

734

728

1,044

43

-20

61

-

0

0

-

0

EXPENSES
Research and development

3,510

3,617

3,626

6,434

6,624

6,984

6,598

7,873

5,232

6,019

6,343

5,403

4,629

3,696

3,593

5,399

2,568

2,743

2,599

2,386

1,149

589

193

0

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,459

0

0

0

0

General and administrative

1,910

1,987

1,912

2,129

2,046

1,847

4,466

2,401

4,210

2,581

6,290

2,830

1,554

1,845

1,672

1,171

1,469

1,545

1,094

992

1,523

744

622

758

Total operating expenses

5,420

5,604

5,538

8,563

8,670

8,831

11,064

10,274

9,442

8,600

12,633

8,233

6,183

5,541

5,265

6,571

4,037

4,288

3,693

20,838

2,672

1,334

815

758

Loss from operations

-5,361

-5,552

-5,123

-8,548

-7,063

-8,533

-9,107

-8,532

-7,425

-7,074

-11,092

-7,628

-4,936

-4,807

-4,537

-5,527

-3,994

-4,308

-3,631

-20,838

-2,672

-1,334

-815

-758

OTHER INCOME/(EXPENSE)
Gain from change in fair value on warrant liability

169

366

1,519

2,504

506

-56

2,954

-741

-3,995

1,628

0

-

0

0

-

-

-

-

-

-

-

-

-

-

Gain from change in fair value of marketable equity securities

830

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from change in fair value of marketable equity securities

-

-1,695

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from change in fair value of marketable equity securities

-

-1,695

1,435

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-88

-95

-106

-114

-112

-114

-125

-132

-128

-139

-147

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-126

-51

-20

-

-1

-5

-4

-2

0

0

0

0

Other expense, net

-4

-6

-37

-390

-140

-25

-9

-

-2

-25

-

-

-6

-1

-

0

0

-2

-0

-

-

-

-

-

Other income/(expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

0

-0

Gain on sale of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

0

0

0

Total other income/(expense), net

907

-1,430

2,811

2,000

254

-195

2,820

-883

-4,125

1,464

-147

-143

-132

-52

-20

0

-1

-7

-4

-4

4

0

0

-0

LOSS BEFORE INCOME TAX BENEFIT

-

-

-

-

-

-

-

-9,415

-11,550

-5,610

-11,239

-7,771

-5,068

-4,859

-4,557

-5,527

-3,995

-4,315

-3,635

-20,842

-2,668

-1,334

-815

-758

Deferred income tax benefit

-

-

-

-

-

-

-

-70

-902

-451

-902

-2,866

-1,561

-1,241

-1,584

-2,200

-2,313

-1,513

-1,349

-3,281

0

0

0

0

NET LOSS

-4,454

-6,982

-2,312

-6,548

-6,809

-8,728

-6,287

-9,345

-10,648

-5,159

-10,337

-4,905

-3,507

-3,618

-2,973

-3,326

-1,682

-2,802

-2,286

-17,561

-2,668

-1,334

-815

-758

Unrealized gain (loss) on available-for-sale securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-0

-0

-

COMPREHENSIVE LOSS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,668

-1,334

-815

-

BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)

-0.08

-0.13

-0.04

-0.11

-0.14

-0.18

-0.13

-0.20

-0.24

-0.12

-0.27

-0.14

-0.09

-0.10

-0.09

-0.12

-0.05

-0.09

-0.07

90.30

-51.62

-25.81

-15.77

-14.69

WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED (in shares)

55,531

55,138

54,185

54,445

49,771

48,511

48,357

46,462

45,193

41,777

38,304

37,910

37,602

34,590

31,670

30,906

30,899

30,576

30,498

30,748

51

51

51

51